Tags: immunotherapy

9/12/2018

Reuters story on kidney cancer drug makes us ask: How is this journalism?

4/17/2018

Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides

4/17/2018

Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark

10/24/2017

Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy

9/21/2017

AP’s story on cancer immunotherapy quickly mentions low success rate

7/18/2017

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

7/13/2017

It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’

6/1/2017

Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results

5/22/2017

Keytruda for bladder cancer: No independent scrutiny of Merck-reported results

4/4/2017

‘Promising’ new lymphoma treatment gets superficial, one-sided coverage by CBS

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

Retweet on Twitter HealthNewsReview.org Retweeted

National Breast Cancer Coalition @NBCCStopBC·

A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold

Reply on Twitter 1520768892888567810 Retweet on Twitter 15207688928885678101 Like on Twitter 15207688928885678103 Twitter 1520768892888567810

HealthNewsReview.org @HealthNewsRevu·

Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's ⁦@CarlaKJohnson⁩. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d

Reply on Twitter 1516522980385472513 Retweet on Twitter 1516522980385472513 Like on Twitter 15165229803854725134 Twitter 1516522980385472513